bimagrumab glp 1 semaglutide Lilly stops trial of muscle-sparing obesity drug Obesity research is moving beyond – A phase 2 clinical trial

In people with type 2 diabetes, the usual effects of GLP-1 may be suppressed or totally absent

As part of the evolving R&D pipeline, Figure 3 summarises the emerging research frontiers into the potential therapeutic applications of GLP-1s beyond cardiometabolic conditions, including neurodegeneration, addiction, mental health, cancer, womens health and asthma

Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis

Higher bmi and the need for larger weight loss When the medical goal is the largest possible reduction in body weight, the highest-magnitude option in the class today is tirzepatide